Back to top

Analyst Blog

Astellas Pharma Inc. (ALPMY) recently received approval for Astagraf XL (tacrolimus extended-release capsules) in the U.S. for the prevention of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction.

Astagraf XL is the first once-daily oral tacrolimus formulation to be approved in the U.S. for patients receiving a kidney transplant.

The approval was based on two primary, randomized, comparative phase III studies which enrolled 1,093 patients in the U.S., Europe, Canada, South America, Australia and South Africa.

This drug is already approved in the EU since 2007 under the trade name Advagraf and in Japan since 2008 under the trade name Graceptor. The drug is approved in 73 countries across the globe.

We note that Astellas’ Prograf (tacrolimus) is available in the U.S. in the form of IV infusion to prevent organ rejection in patients who have had a kidney, liver or heart transplant. Prograf generated global sales of 161.7 billion yen in 2012, including 49.4 billion yen from Japan, 31.4 billion yen from the Americas, 57.5 billion yen from Europe and 18.9 billion yen from Asia.

Prograf patents expired in the U.S. in Apr 2008 and in major European countries in Jun 2009.

Currently, Prograf faces generic competition in the U.S. Generic versions of Prograf were launched by companies like Mylan Inc (MYL - Analyst Report) and Dr. Reddy's Laboratories Ltd. (RDY - Analyst Report).

Astellas carries a Zacks Rank #4 (Sell). Right now, Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) looks well positioned with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
STRATTEC SE… STRT 85.29 +6.29%
SUPER MICRO… SMCI 26.01 +6.21%
CENTURY ALU… CENX 26.19 +4.84%
TESLA MOTOR… TSLA 278.00 +3.08%
BAIDU ADS BIDU 221.06 +3.05%